CHICAGO, March 20, 2013 /PRNewswire/ — Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a global leader in musculoskeletal health, today introduced Gel-One® Cross-linked Hyaluronate at the 2013 American Academy of Orthopaedic Surgeons Annual Meeting. Gel-One Hyaluronate is an injectable gel approved for the treatment of osteoarthritis of the knee. The product is the first low-volume viscosupplement designed to provide pain relief and improve knee joint function through a single-injection treatment.
“Zimmer is committed to meeting osteoarthritis patients at every stage of the continuum of care, and this innovative cushioning gel offers therapy with the simplicity of a single, in-office injection,” said David Nolan , Zimmer Senior Vice President. “Gel-One Hyaluronate is a supplement to natural synovial fluid, offering pain relief to patients living with knee osteoarthritis. We are excited to introduce this joint preservation technology to surgeons and their patients in the United States.”
Gel-One Hyaluronate is indicated for the treatment of pain in knee osteoarthritis patients who have failed to respond to non-pharmacologic therapy, non-steroidal anti-inflammatory drugs (NSAIDs), or simple analgesics such as acetaminophen. Unlike other viscosupplement treatments, highly purified Gel-One Hyaluronate requires only 3mL for safe and effective treatment. Gel-One Hyaluronate is manufactured using a unique cross-linking process that enables increased viscoelasticity.
In a clinical study, Gel-One Hyaluronate demonstrated statistically significant pain relief over a Phosphate Buffered Saline control (PBS). Patients receiving Gel-One Hyaluronate experienced, on average, a nearly 40 percent reduction in pain from baseline (28 mm reduction in WOMAC pain on a 100 mm VAS, Visual Analog Scale).
For more information about Gel-One Hyaluronate, visit Zimmer at Booth 529 at the 2013 American Academy of Orthopaedic Surgeons annual meeting in Chicago, or go to www.zimmer.com.
Gel-One® is a registered trademark of Seikagaku Corporation.